Kornimate/medical-research-clean huggingface dataset:
micro ribonucleic acid (rna) as cholinergic tone and inflammatory regulator in inflammatory bowel disease

Conditions: Inflammatory Bowel Disease

Summary: there is a reciprocal relationship between the central nervous system and the immune system. stimulation of the vagus nerve results in secretion of acetylcholine (ach) which decreases secretion of pro-inflammatory cytokines. acetylcholine esterase is an enzyme that neutralizes ach and thus, involves in regulation of ach levels, and in the cholinergic tone and inflammatory state. micrornas (mirs) are evolutionarily conserved, rnas that regulate gene expression. the investigators hypothesized that mirs controlling systemic communication processes function in one tissue in response to signals (i.e. neuronal, hormonal or others) from another. specifically, the investigators hypothesized that mirs control the inflammatory response in inflammatory bowel diseases through regulation of expression of messenger rna of ache.


Eligibility criteria:
inclusion criteria: * inflammatory bowel disease patients under going colonoscopy exclusion criteria: * debilitated patients who need an apotropsy * age \ 75 * pregnant women * evidence of previous or current cancer * inflammatory disease other than ibd

Keywords: inflammatory bowel disease micro rna cholinergic tone inflammation
personalized anticoagulant therapy for pulmonary thromboembolism

Conditions: Pulmonary Thromboembolisms; Anticoagulants; Increased

Summary: the goal of this prospective observational study is to explore the influencing factors of the efficacy and safety of anticoagulant therapy for pulmonary thromboembolism in special populations with older age, renal insufficiency or co-existing malignancy, and establish a predictive model to guide clinical practice. the main questions it aims to answer are: * to analyze the influencing factors of the efficacy and safety of anticoagulant therapy for specific populations with pulmonary thromboembolism (pte) in the real world (such as the elderly, those with impaired kidney function, and individuals with malignant tumors). * whether we can use machine-learning models to predict bleeding events and vte recurrence in special populations following anticoagulant therapy in the real world? participants will receive diagnostic and therapeutic measures for pulmonary thromboembolism in accordance with clinical guidelines, including anticoagulant therapy. some patients need to have peripheral blood samples collected at the time of enrollment and 3 months after anticoagulant therapy.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old; 2. adult patients with objectively diagnosed pulmonary thromboembolism (pte) (with or without concomitant deep vein thrombosis); 3. specific populations meeting any of the following criteria: elderly patients (≥75 years old); patients with impaired kidney function (creatinine clearance estimated by the cockcroft-gault formula, crcl \< 60ml/min); patients with active malignancies (under treatment or with unrecovered malignancies); 4. patients who have not started anticoagulant therapy before enrollment and are planned for anticoagulant treatment after evaluation by the attending physician; 5. ecpected life expectancy longer than 3 months. 6. patients who understand and agree to participate in this study, sign the informed consent form, and adhere to regular follow-up visits. exclusion criteria: 1. moderate or severe liver dysfunction (child-pugh class b or c); 2. spontaneous bleeding tendency, such as coagulation disorders or thrombocytopenia (plt\<20×10\^9/l); 3. contraindications to anticoagulant drugs, including allergy to anticoagulants, clinically significant active bleeding, significant risk of major bleeding due to lesions or conditions, significantly abnormal coagulation function, liver disease with clinically relevant bleeding risk, thrombocytopenia, etc., as determined by the attending physician; 4. high-risk pulmonary embolism requiring thrombolysis; 5. patients currently participating in other clinical trials.
a study of ly3437943 in chinese participants with obesity or overweight

Conditions: Overweight; Obesity

Summary: the main purpose of this study is to learn about the safety and tolerability of ly3437943 when given to chinese participants with overweight body mass index (bmi) or obesity. blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. each enrolled participant will receive injections of ly3437943 or placebo given just under the skin. for each participant, the study will last about 20 weeks excluding screening period and may include up to 20 visits to the study center.


Eligibility criteria:
inclusion criteria: for all participants: * are native chinese males or females * have a body mass index of ≥27 and ≤40 kilograms per square meter (kg/m²) * have not modified diet or adopted any nutritional lifestyle modification for 3 months * have stable body weight for the last three months * male participants must agree to use contraception during the study and for 4 months afterward and female participants must be woman of nonchildbearing potential for type 2 diabetes mellitus (t2dm) participants: * have type 2 diabetes for at least 3 months * have a glycated hemoglobin (hba1c) value of ≥7.0% and ≤10.5% and have been treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening exclusion criteria: for all participants: * have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week and smoke more than 10 cigarettes, or cigarette equivalent (as determined by investigator), per day * have other serious or unstable illnesses * have had an episode of severe hypoglycemia * current or chronic history of liver disease. for t2dm participants: * have type 1 diabetes mellitus * have uncontrolled diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization * any glucose-lowering medications other than metformin within 3 months prior to screening
a study investigating the safety of ro7795081 and the effect of ro7795081 on how the body processes pitavastatin and rosuvastatin in otherwise healthy overweight or obese adult participants

Conditions: Overweight; Obesity

Summary: this is a randomized, investigator-and-participant-blind, placebo-controlled, fixed sequence, cross-over, phase 1 study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of orally administered ro7795081 and the effect of a steady-state dose of orally administered ro7795081 on the pharmacokinetics of pitavastatin and rosuvastatin in otherwise healthy, overweight or obese adult participants.


Eligibility criteria:
inclusion criteria: * healthy participants with no clinically relevant findings on physical examination at screening and at baseline (including detailed medical and surgical history, vital signs, 12-lead ecg, hematology, blood chemistry, and urinalysis); with no suspicion of cognitive impairment or dementia as judged by the investigator; who are not under judicial supervision, guardianship, or curatorship. * body mass index (bmi) ≥27.0 kg/m\^2 at screening and on day -1 of period 1 * stable body weight (defined as \<5% gain or loss) in the 2 months prior to screening as per verbal report by the participant and for the period between screening and day -1 of period 1 as per measured weight * agreement to adhere to the contraception requirements exclusion criteria: * pregnant, breastfeeding, or intending to become pregnant during the study or within 34 days after the last study drug administration * any condition or disease detected during the medical interview or physical examination that would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study in the opinion of the investigator * history or presence of any clinically significant cardiovascular, broncho-pulmonary, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological, psychiatric, or metabolic disorders, allergic diseases, hypofertility, cancer, or cirrhosis * history or evidence of any medical condition capable of significantly altering the absorption, metabolism, or elimination of drugs * history of convulsions (other than benign febrile convulsions of childhood) including epilepsy, or personal history of significant cerebral trauma or cns infections (e.g., meningitis) * history of acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma
influenza viral challenge study of cc-42344 in healthy participants

Conditions: Influenza A

Summary: participants in this study will be given either cc-42344 (one of two dose levels) or placebo orally for 5 days after receiving an influenza (flu) challenge virus. participants will not know whether they are getting placebo or cc-42344. the amount of virus in nasal samples will be measured over time. side effects and pharmacokinetics (the amount of cc-42344 in blood) will also be measured.

this is a single-center, phase 2a, randomized, double-blind, placebo-controlled study in healthy adult participants. the primary goal of this study is to assess the antiviral activity of orally administered cc-42344 in an influenza human viral challenge model, and to explore the impact of different dose levels on efficacy. in addition, the safety, tolerability, and pharmacokinetics will be assessed.

Eligibility criteria:
inclusion criteria: * healthy adults * body weight ≥50 kg * body mass index ≥18 kg/m2 and ≤35 kg/m2 * serology results consistent with susceptibility to challenge virus infection exclusion criteria: * history of or current significant medical condition * upper or lower respiratory tract infection within 4 weeks * vaccination within 4 weeks

Keywords: tolerability antiviral viral challenge model
adult autoimmune myopathies (maia)

Conditions: Idiopathic Inflammatory Myopathies

Summary: this study corresponds to a monocentric prospective cohort of adult patients presenting a suspicion of idiopathic inflammatory myopathy. it will allows the constitution of an organized collection of longitudinal clinical data as well as collection of biological samples, including blood sample, urine, stool and muscle specimen.


Eligibility criteria:
inclusion criteria: * clinical suspicion of adult inflammatory myopathy * social security affiliation exclusion criteria: * pregnant and lactating women * patients unable to consent * patients refusing to participate in the research. * patients under legal protection
impact of oxygen therapy on fatigue in patients with hypermobile-type ehlers-danlos syndrome

Conditions: Ehlers-Danlos Syndrome

Summary: the hypothesis of the oxysed study is that the delivery of 3 months of oxygen therapy via an oxygen concentrator would reduce fatigue, pain, headaches, kinesiophobia, drug intake, dyspnea, and improve walking performance, quality of sleep and quality of life of patients with ehlers danlos syndrome hypermobility type (eds / ht).


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years; * diagnosed with eds/ht defined by the new york critieria; * with intense fatigue defined by an fss ≥ 4; * having given free and informed written consent; * speaking french language; * being affiliated with or benefiting from a social security scheme. exclusion criteria: * with progressive parenchymal pulmonary pathology (pulmonary fibrosis, post-smoking emphysema); * having an ongoing pregnancy or breastfeeding; * who have already received oxygen therapy for the eds / ht indication in the last 6 months; * having a pathology that causes fatigue, which is not compensated or treated; non-exhaustive list anemia, sleep apnea syndrome, psychiatric pathologies including severe depression, organ failure (cardiac, renal, respiratory, hepatic), endocrinopathies (hypo or hyperthyroidism, diabetes), nutritional deficiencies; * subject to a measure for the protection of justice.
a study to explore treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with acute myeloid leukemia (aml) receiving venetoclax through chart review

Conditions: Acute Myeloid Leukemia

Summary: acute myeloid leukemia (aml), also referred to as acute myelogenous leukemia or acute non-lymphocytic leukemia, is a relatively rare, yet aggressive, type of cancer. this study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with aml receiving venetoclax. data from up to 700 participants will be collected. no participants will be enrolled in this study. participants' charts will be reviewed. no drug will be administered as a part of this study. the duration of the observation period is up to 10 months. there is no additional burden for participants in this trial. all visits must be completed prior to data extraction and participants will be followed for up to 10 months.


Eligibility criteria:
inclusion criteria: * the participant received a diagnosis for acute myeloid leukemia (aml). * the participant was initiated on the studied line of therapy for previously untreated aml, as noted in the protocol. * the participant was treated with the studied line of therapy at least 28 days prior to date of data collection. * information on the participant's treatments, selected (or important) clinical characteristics, and outcomes is available from the start of the studied line of therapy onwards. exclusion criteria: * the participant received the studied line of therapy as part of a clinical trial. * participant received prior lines of therapy for aml. * the participant has a history of malignancies within 2 years prior to the studied line of therapy, other than aml, and with the exception of what is noted in the protocol.

Keywords: acute myeloid leukemia cancer venetoclax: venclyxto abt-199
the impact of swallowing intervention for elderly community dwellers

Conditions: Dysphagia

Summary: the goal of this clinical trial is to explore the impact of systematic simple swallowing training on swallowing function and quality of life in community-dwelling elderly individuals (≥60 year old) with swallowing disorders. it primarily aims to address two key aspects: 1) the prevalence of dysphagia among community-dwelling elderly individuals, and 2) the effects of systematic simple swallowing training on swallowing function and quality of life in community-dwelling elderly individuals with swallowing disorders. all participants are divided into 2 groups. the intervention group is required to undergo a continuous three-week (21 days) systematic simple swallowing training, with weekends off and training conducted only on weekdays. the training will be conducted two sessions per day, lasting 15-20 minutes each.

the investigators have designed a simple and user-friendly swallowing rehabilitation training method called "systematic simple swallowing training" based on commonly used swallowing training techniques in the department of rehabilitation medicine and the prevalent pathological causes of swallowing disorders in the elderly. it has shown promising preliminary efficacy. the goal of this clinical trial is to explore the impact of systematic simple swallowing training on swallowing function and quality of life in community-dwelling elderly individuals (≥60 year old) with swallowing disorders. it primarily aims to address two key aspects: 1) the prevalence of dysphagia among community-dwelling elderly individuals, and 2) the effects of systematic simple swallowing training on swallowing function and quality of life in community-dwelling elderly individuals with swallowing disorders. all participants are divided into 2 groups. the intervention group is required to undergo a continuous three-week (21 days) systematic simple swallowing training, with weekends off and training conducted only on weekdays. the training will be conducted two sessions per day, lasting 15-20 minutes each.

Eligibility criteria:
inclusion criteria: * age over 60 years old. * no hospitalization within the past six months. * with clear consciousness and able to cooperate with questionnaires and training. * the elderly people who voluntarily participate and agree to adhere until the end of the study. * early dysphagia. exclusion criteria: * complicated with severe liver and kidney failure, tumors, or hematological disorders. * physical disability. * difficulty in mobility. * simultaneously receiving other therapies that might influence this study. * individuals with a gastrostomy. * abnormalities of the oral, pharyngeal, or esophageal structures.
developing a telehealth + mhealth cannabis use intervention for young adults

Conditions: Cannabis Use Disorder

Summary: the goal of this clinical trial is to determine 1) feasibility of the moment-v intervention for cannabis use disorder in young adults, 2) feasibility of conducting the trial remotely, and 3) whether the moment-v intervention reduces cannabis use frequency and problems. researchers will compare the moment-v intervention to usual care enhanced by a counselor meeting. participants will either meet with a counselor two times and use an app on their phone for two weeks, or meet with a counselor briefly one time. all participants will be asked to complete electronic surveys, interviews with a research assistant, and saliva drug testing at home over three months.


Eligibility criteria:
for the oral fluid testing pilot inclusion criteria: * primary care patient of the boston children's hospital adolescent/young adult medicine practice * participation in moment-v open pilot * ownership of a smartphone * availability for the 2-week study duration exclusion criteria: * inability/unwillingness to provide contact information * current pregnancy or parenting for the pilot rct inclusion criteria: * primary care patient of the boston children's hospital adolescent/young adult medicine practice or martha eliot health center adolescent clinic * 18 to 26 years old * cannabis use disorders identification test-revised (cudit-r) score of ≥12 * recreational cannabis use on \&gt;3 days/week, on average, in the past 30 days * ownership of a smartphone that is pin- or password-protected * ability to read and speak english * availability for the 6-month study duration exclusion criteria: * inability/unwillingness to provide contact information * written certification from a physician for marijuana for medical use * current participation in a substance use treatment program or research study * current pregnancy or parenting * participation in prior moment or moment-v research

Keywords: cannabis use behavioral intervention young adult
performance assessment tests in working individuals with dme following treatment with ranibizumab

Conditions: Diabetic Macular Edema

Summary: performance assessment testing may be a useful tool to evaluate the impact of ranibizumab on day-to-day visual function in patients with diabetic macular edema (dme).


Eligibility criteria:
inclusion criteria: * ability to provide written informed consent and comply with study assessments for the full duration of the study * age 18 ≤ x ≤ 65 years and currently employed at the baseline study visit * diagnosis of diabetes mellitus (type 1 or 2) o any one of the following will be considered to be sufficient evidence that diabetes is present: * current regular use of insulin for treatment of diabetes * current regular use of oral anti-hyperglycemia agent for the treatment of diabetes * clinical evidence of retinal thickening due to macular edema involving the center of the macula, associated with diabetic retinopathy. * central diabetic macular edema present on clinical examination or or evidence indicating disease activity on spectral domain oct. * visual acuity score greater than or equal to 19 letters (20/400) and less than or equal to 73 letters (20/40) by the etdrs visual acuity protocol. * media clarity, pupillary dilation and patient cooperation sufficient to allow oct testing and retinal photography exclusion criteria: * pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception. * participation in another ocular investigation or trial simultaneously * blood pressure \> 180/110 (systolic above 180 or diastolic above 110) * any condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism, drug abuse) * evidence of vitreoretinal interface abnormality after ocular exam or oct that may be contributing to the macular edema * an eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of subretinal fibrosis or geographic atrophy) * presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (e.g. amd, uveitis, irvine-gas) * evidence of active neovascularization of the iris or retina * evidence of central atrophy or fibrosis in the study eye * presence of substantial cataract, one that might decrease the vision by 3 or more lines of vision at sometime during the study. * previous use of intraocular or periocular corticosteroids in the study eye in the previous 120 days * previous treatment with anti-angiogenic drugs in the study eye i.e. pegaptanib sodium, bevacizumab, ranibizumab, aflibercept within 120 days prior to baseline * history of vitreous surgery in the study eye * history of cataract surgery within 3 months of enrollment. * history of yag capsulotomy within 2 months of enrollment. * visual acuity \<20/400 in the fellow eye * uncontrolled glaucoma (pressure \>30) despite treatment with glaucoma medications. * history of cerebral vascular accident or myocardial infarction within 3 months prior to day 0.
effect of pursed lips breathing on chest wall, mobility diaphragmatic and exercise tolerance in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study aimed to evaluate the acute effect of plb technique on diaphragmatic mobility, the kinematics of the thoracoabdominal complex analysis of lung volumes and exercise tolerance in patients with chronic obstructive pulmonary disease (copd). this is a study randomized cross-over clinical trial and blind, in subjects with chronic obstructive pulmonary disease (copd) according to criteria of the global initiative for chronic obstructive lung disease (gold) (fev1 / fvc \<0.7 and fev1 \<80% predicted) selected at the clinical hospital of the federal university of pernambuco (ufpe) and otavio de freitas general hospital (hgof). the investigators recruited 13 patients copd (according to previous sample calculation) aged between 40 and 80 years, of both sexes. the first day was held evaluation of lung function, respiratory muscle strength, body composition, dyspnea index and functional capacity. on the second day was held evaluation of thoracoabdominal complex kinematics by plethysmography optoelectronics (oep) with quiet breathing (qb) or pursed-lips breathing (plb). lung volumes with 2 minutes with qb and 6 minutes plb or only 6 minutes by qb as randomization were observed. before and after performing the requested breathing pattern diaphragmatic mobility was observed by ultrasonography (us) and requested the patient an inspiratory capacity maneuver (ic). the evaluator who performed the ultrasound was blinded as to the beginning of the breathing pattern of order performed by the patient.


Eligibility criteria:
inclusion criteria: * copd diagnosis with stage ii-iv (gold), * stable clinical condition (no exacerbation or hospital admission in the last four weeks preceding the study) * absence of other disease that may potentially contribute to dyspnea (heart disease, congestive heart failure, neuromuscular diseases, severe postural changes) exclusion criteria: * bmi\> 30 kg / m2 * musculoskeletal limitations * use of oxygen therapy * extreme discomfort during the procedure application

Keywords: chronic obstructive pulmonary disease respiratory mechanics plethysmography diaphragm respiratory muscles breathing exercises